Patents by Inventor James M. Binley

James M. Binley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized viral envelope proteins and uses thereof
    Patent number: 7592014
    Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 22, 2009
    Assignees: Progenics Pharmaceuticals Inc., Aaron Diamond Aids Research Centre (ADARC)
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
  • Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins
    Patent number: 7479553
    Abstract: This invention provides a DNA which upon transcription produces an RNA encoding a modified HIV-1 gp140 polypeptide, which polypeptide upon cleavage produces a modified gp120 and a modified ectodomain of gp41 which together form a complex exhibiting enhanced binding to HIV-1 neutralizing antibodies and reduced binding to HIV-1 non-neutralizing antibodies, wherein the modifications comprise an A492C mutation in gp120 and a T596C mutation in gp41, said mutations being numbered by reference to the HIV-1 isolate JR-FL, and resulting in a disulfide bond between gp120 and ectodomain gp41 which stabilizes the otherwise non-covalent gp120-gp41 interaction.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: January 20, 2009
    Assignees: Progenics Pharmaceuticals, Inc., Aaron Diamond AIDS Research Centre (ADARC)
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
  • Stabilized viral envelope proteins and uses thereof
    Patent number: 7022324
    Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: April 4, 2006
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
  • Stabilized viral envelope proteins and uses thereof
    Publication number: 20040224308
    Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
    Type: Application
    Filed: February 18, 2004
    Publication date: November 11, 2004
    Applicants: Progenics Pharmaceuticals, Inc., Aaron Diamond AIDS Research Centre
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
  • Stabilized viral envelope proteins and uses thereof
    Patent number: 6710173
    Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: March 23, 2004
    Assignees: Progenics Pharmaceuticals, Inc., Aaron Diamond AIDS Research Centre (ADARC)
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
  • Stabilized viral envelope proteins and uses thereof
    Publication number: 20030052839
    Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
    Type: Application
    Filed: December 21, 2001
    Publication date: March 20, 2003
    Applicant: Progenics Pharmaceuticals, Inc., Aaron Diamonds AIDS Research Center (ADARC)
    Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore